MedTrace Logo

Influenza Vaccine in HIV Study

NCT02632578 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 57

Last updated 2015-12-16

No results posted yet for this study

Summary

The aims of this study are:

1. to investigate if HIV infection alters the antibody responses to influenza and
2. to assess the ability of licensed influenza vaccine to induce functional non-neutralising antibodies in HIV-infected and HIV-uninfected subjects.

Conditions

  • Influenza, Human

Interventions

BIOLOGICAL

2015 Fluvax® vaccine, BioCSL (a licensed influenza vaccine)

Subjects received licensed influenza vaccine (Fluvax®), 1ml intramuscular injection.

Sponsors & Collaborators

Principal Investigators

  • Stephen Kent, Professor · University of Melbourne

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-02-28
Primary Completion
2015-06-30
Completion
2015-12-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02632578 on ClinicalTrials.gov